Clinical Trial Update: Open Label Study of Long Term Safety Evaluation of Alirocumab [Phase 3]

View source ↗

Summary

Open-label, long-term safety study of Alirocumab (Praluent) in adults with hypercholesterolemia. Phase 3 trial results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2018-07-24